文献速递炎症性肠病

接受抗TNF治疗的炎症性肠病患者继续或停用5-氨基水杨酸:一项全国性人群研究

Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study.
PubMed 文献 · Aliment Pharmacol Ther · 2024-06-12

该研究基于韩国国民健康保险数据库2007-2020年数据,比较开始抗TNF治疗后90天内停用或继续使用5-氨基水杨酸(5-ASA)的炎症性肠病(IBD)患者结局。纳入7442例患者,中位随访4.3年,停用5-ASA与不良临床事件风险增加无关(校正风险比1.01,95%置信区间0.93-1.10),各组累积发生率无显著差异。

要点

  • 开始抗TNF后90天内停用5-ASA与继续使用相比,不良临床事件风险无显著差异。
  • 不良临床事件复合终点包括新用糖皮质激素、IBD相关住院或肠道手术。
  • 克罗恩病和溃疡性结肠炎亚组分析均显示停用与继续5-ASA的不良事件风险无差异。

核心结论

  • 在开始抗TNF治疗后停用5-ASA与IBD患者不良临床事件风险增加无关。

研究设计与样本

  • 基于韩国国民健康保险索赔数据库2007年至2020年数据的全国性人群研究。
  • 纳入开始抗TNF治疗后90天内停用或继续5-ASA的IBD患者共7442例,其中克罗恩病4479例(60.2%),溃疡性结肠炎2963例(39.8%)。
  • 比较停用与继续5-ASA两组患者的临床结局,中位随访4.3年。

主要发现

  • 1037例(13.9%)患者在开始抗TNF治疗后90天内停用5-ASA。
  • 停用5-ASA与不良临床事件风险无关(校正风险比1.01,95%置信区间0.93-1.10)。
  • 各不良临床事件及复合终点的累积发生率在两组间均无显著差异(所有p>0.05)。
  • 克罗恩病和溃疡性结肠炎队列分别分析显示,5-ASA继续组与停用组的不良临床结局无差异。
  • 按推测的疾病复发危险因素进行亚组分析,两组不良事件风险无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of continuing or stopping 5-aminosalicylates (5-ASA) after commencing anti-tumour necrosis factor (anti-TNF) therapy in patients with inflammatory bowel disease (IBD) remains unclear. AIMS: To compare the outcomes of patients with IBD who stopped or continued 5-ASA after starting anti-TNF therapy. METHODS: We analysed data from the Korean National Health Insurance claims database between 2007 and 2020. We compared the clinical outcomes of patients who stopped or continued 5-ASA within 90 days of anti-TNF initiation. The primary outcome was any adverse clinical event defined as a composite of new corticosteroid use, IBD-related hospitalisation, or intestinal surgery. RESULTS: Among 7442 patients included for analysis (4479 [60.2%] with Crohn's disease [CD] and 2963 [39.8%] with ulcerative colitis [UC]), 1037 (13.9%) discontinued 5-ASA within 90 days of starting anti-TNF therapy. During a median 4.3-year follow-up, discontinuation of 5-ASA was not associated with an increased risk of adverse clinical events (adjusted hazard ratio 1.01, 95% confidence interval 0.93-1.10). The cumulative incidence of each adverse clinical event and the composite outcome were not significantly different between groups (all, p > 0.05). Additionally, separate analyses in CD and UC cohorts revealed no differences in adverse clinical outcomes between the 5-ASA continuation and discontinuation groups. Subgroup analyses by presumed risk factors for disease relapse showed no significant differences in the risk of adverse events between groups. CONCLUSIONS: In this nationwide population-based study, discontinuing 5-ASA after starting anti-TNF therapy was not associated with an increased risk of adverse events in patients with IBD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Seo J, Kim S, Hong SW, et al. Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study. Aliment Pharmacol Ther. 2024. PMID: 38866064. doi:10.1111/apt.18102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。